Ultragenyx Pharmaceutical (RARE) News Today $42.59 -1.89 (-4.25%) Closing price 04:00 PM EasternExtended Trading$42.56 -0.03 (-0.07%) As of 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Canaccord Genuity Group Increases Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $136.00February 20 at 2:31 AM | americanbankingnews.comUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)February 19 at 4:30 PM | globenewswire.comUltragenyx Pharmaceutical (NASDAQ:RARE) Given New $136.00 Price Target at Canaccord Genuity GroupCanaccord Genuity Group lifted their price target on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a "buy" rating in a report on Tuesday.February 19 at 8:07 AM | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Acquired by Peregrine Capital Management LLCPeregrine Capital Management LLC increased its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 22.1% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 163,888 shares of the biopharmaceutical company's stock afterFebruary 19 at 5:15 AM | marketbeat.comUltragenyx price target raised to $136 from $121 at CanaccordFebruary 18 at 8:51 PM | markets.businessinsider.comBarclays Sticks to Their Buy Rating for Ultragenyx Pharmaceutical (RARE)February 18 at 8:51 PM | markets.businessinsider.comAMERICAN SALARS ACQUIRES 18,083 HECTARE BRAZIL HARDROCK LCT PEGMATITE PROPERTY WITH RECENT SAMPLING UP TO 3.72% LI20 AND SIGNIFICANT RARE EARTHÂ ELEMENTÂ VALUESFebruary 18 at 4:00 AM | globenewswire.comUltragenyx Pharmaceutical's (RARE) Buy Rating Reaffirmed at HC WainwrightFebruary 16, 2025 | americanbankingnews.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?February 15, 2025 | finance.yahoo.comHC Wainwright Reiterates "Buy" Rating for Ultragenyx Pharmaceutical (NASDAQ:RARE)HC Wainwright reissued a "buy" rating and issued a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Friday.February 15, 2025 | marketbeat.comGoldman Sachs maintains buy on Ultragenyx, target at $78February 14, 2025 | msn.comBreaking Down Ultragenyx Pharmaceutical: 7 Analysts Share Their ViewsFebruary 14, 2025 | benzinga.comUltragenyx Pharmaceutical (RARE) Gets a Buy from RBC CapitalFebruary 14, 2025 | markets.businessinsider.comUltragenyx Pharmaceutical (NASDAQ:RARE) Announces Earnings ResultsUltragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) released its quarterly earnings results on Thursday. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative return on equity of 187.12% and a negative net margin of 106.93%.February 14, 2025 | marketbeat.comUltragenyx reports Q4 EPS ($1.39), consensus ($1.27)February 14, 2025 | markets.businessinsider.comUltragenyx stock holds Buy rating, $140 target from TruistFebruary 14, 2025 | msn.comUltragenyx projects $640M-$670M in 2025 revenue growth driven by product launchesFebruary 14, 2025 | msn.comUltragenyx Pharmaceutical Inc. (RARE) Q4 2024 Earnings Call TranscriptFebruary 13, 2025 | seekingalpha.comUltragenyx Pharmaceutical Inc. 2024 Q4 - Results - Earnings Call PresentationFebruary 13, 2025 | seekingalpha.comUltragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate UpdateFebruary 13, 2025 | globenewswire.comFrank Sands Reduces Stake in Ultragenyx Pharmaceutical Inc.February 12, 2025 | gurufocus.comWCM Investment Management LLC Cuts Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)WCM Investment Management LLC lessened its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 6.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 135,609 shaFebruary 10, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock Position Lifted by abrdn plcabrdn plc grew its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 25.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 317,125 shares of the biopharmaceutical company's stock after acquiring an adFebruary 8, 2025 | marketbeat.comUltragenyx Pharmaceutical (RARE) Expected to Announce Earnings on ThursdayUltragenyx Pharmaceutical (NASDAQ:RARE) will be releasing earnings before the market opens on Thursday, February 13, Financial Modeling Prep reports.February 8, 2025 | marketbeat.comMorgan Stanley Remains a Buy on Ultragenyx Pharmaceutical (RARE)February 6, 2025 | markets.businessinsider.comUltragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate UpdateFebruary 6, 2025 | globenewswire.comUltragenyx reports positive data on gene therapy for rare diseaseFebruary 5, 2025 | msn.comUltragenyx announces new data on UX111 AV gene therapyFebruary 5, 2025 | markets.businessinsider.comUltragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome Type A (MPS IIIA) Correlated with Sustained Reductions in CSF-HSFebruary 5, 2025 | globenewswire.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Recommendation of "Moderate Buy" by BrokeragesUltragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the fourteen research firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and thirteen haveFebruary 3, 2025 | marketbeat.comKBC Group NV Increases Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)KBC Group NV raised its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 2,275.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 61,010 shares of the biopharmaceutical company's stFebruary 2, 2025 | marketbeat.comUltragenyx Pharmaceutical: Advancing On Multiple FrontsJanuary 30, 2025 | seekingalpha.comWhat is Wedbush's Estimate for RARE FY2024 Earnings?Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Equities researchers at Wedbush boosted their FY2024 earnings per share estimates for Ultragenyx Pharmaceutical in a research report issued on Thursday, January 23rd. Wedbush analyst L. Chico now anticipates that the biopharmaceutical cJanuary 27, 2025 | marketbeat.comWhat is Wedbush's Forecast for RARE FY2027 Earnings?Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Investment analysts at Wedbush increased their FY2027 earnings per share estimates for Ultragenyx Pharmaceutical in a report released on Thursday, January 23rd. Wedbush analyst L. Chico now expects that the biopharmaceutical company wilJanuary 24, 2025 | marketbeat.comUltragenyx's SWOT analysis: rare disease stock poised for growthJanuary 23, 2025 | msn.comUltragenyx Pharmaceutical's (RARE) "Overweight" Rating Reiterated at Cantor FitzgeraldCantor Fitzgerald reaffirmed an "overweight" rating and issued a $118.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Wednesday.January 22, 2025 | marketbeat.comCantor Fitzgerald Predicts RARE FY2025 EarningsUltragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Ultragenyx Pharmaceutical in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska anticipates that the biopJanuary 22, 2025 | marketbeat.comWhat is Leerink Partnrs' Forecast for RARE FY2024 Earnings?Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Analysts at Leerink Partnrs upped their FY2024 earnings per share estimates for Ultragenyx Pharmaceutical in a report released on Monday, January 20th. Leerink Partnrs analyst J. Schwartz now expects that the biopharmaceutical company wJanuary 22, 2025 | marketbeat.comAssenagon Asset Management S.A. Sells 76,160 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Assenagon Asset Management S.A. lessened its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 52.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 69,273 shares of thJanuary 22, 2025 | marketbeat.comWhy Ultragenyx Pharmaceutical (RARE) Is the Biotech Stock with the Biggest Upside PotentialJanuary 17, 2025 | msn.comUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)January 17, 2025 | globenewswire.comFY2024 EPS Estimates for RARE Raised by Cantor FitzgeraldUltragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Equities research analysts at Cantor Fitzgerald upped their FY2024 earnings estimates for shares of Ultragenyx Pharmaceutical in a research note issued to investors on Wednesday, January 15th. Cantor Fitzgerald analyst K. Kluska now forJanuary 17, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Sold by Hennion & Walsh Asset Management Inc.Hennion & Walsh Asset Management Inc. lessened its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 19.0% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 63,January 17, 2025 | marketbeat.comUltragenyx Pharmaceutical (NASDAQ:RARE) Shares Down 5.7% - Should You Sell?Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Down 5.7% - Here's What HappenedJanuary 16, 2025 | marketbeat.comEvercore ISI Remains a Buy on Ultragenyx Pharmaceutical (RARE)January 16, 2025 | markets.businessinsider.comUltragenyx Pharmaceutical (NASDAQ:RARE) Trading Up 9.1% - Here's What HappenedUltragenyx Pharmaceutical (NASDAQ:RARE) Trading 9.1% Higher - Time to Buy?January 15, 2025 | marketbeat.comPositive Outlook on Ultragenyx Pharmaceuticals Driven by Strong Financials and Promising PipelineJanuary 15, 2025 | markets.businessinsider.comUltragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Down 5.7% - Time to Sell?Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Down 5.7% - Should You Sell?January 14, 2025 | marketbeat.comTD Cowen Sticks to Their Buy Rating for Ultragenyx Pharmaceutical (RARE)January 13, 2025 | markets.businessinsider.comUltragenyx Pharmaceutical (RARE) Receives a Hold from WedbushJanuary 13, 2025 | markets.businessinsider.com Get Ultragenyx Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter. Email Address RARE Media Mentions By Week RARE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RARE News Sentiment▼0.290.60▲Average Medical News Sentiment RARE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RARE Articles This Week▼146▲RARE Articles Average Week Get Ultragenyx Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Genmab A/S News Intra-Cellular Therapies News Viatris News Moderna News Dr. Reddy's Laboratories News Vaxcyte News Sarepta Therapeutics News Qiagen News Ascendis Pharma A/S News Roivant Sciences News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RARE) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ultragenyx Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
